Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
6 studies found for:    weill AND intra arterial infusion | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Phase I/II Trial Of Super-Selective Intraarterial Infusion Of Erbitux and Bevacizumab For Treatment Of Relapsed/Refractory Intracranial Glioma In Patients Under 22 Years Of Age
Conditions: Glioblastoma Multiforme;   Fibrillary Astrocytoma of Brain;   Glioma of Brainstem;   Anaplastic Astrocytoma;   Pilomyxoid Astrocytoma;   Mixed Oligodendroglioma-Astrocytoma;   Brain Stem Glioma;   Diffuse Intrinsic Pontine Glioma;   High Grade Glioma
Intervention: Drug: SIACI of Erbitux (200 m/m2) and Bevacizumab(15 mg/kg)
2 Recruiting Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab)
Conditions: Glioblastoma Multiforme;   Anaplastic Astrocytoma
Intervention: Drug: Super-Selective Intraarterial Intracranial Infusion of BEVACIZUMAB
3 Recruiting Intra-arterial Chemotherapy for Spinal Metastases
Conditions: Spinal Diseases;   Spinal Metastases;   Spinal Tumors
Intervention: Drug: Melphalan (intra-arterial infusion)
4 Recruiting Intraarterial Cerebral Infusion of Avastin for Vestibular Schwannoma (Acoustic Neuroma)
Condition: Vestibular Schwannoma
Intervention: Drug: Bevacizumab (Avastin)
5 Recruiting Super-Selective Intraarterial Cerebral Infusion of Cetuximab for the Treatment of Recurrent Glioblastoma Multiforme and Anaplastic Astrocytoma
Conditions: Glioblastoma Multiforme (GBM);   ANAPLASTIC ASTROCYTOMA (AOA)
Intervention: Drug: Superselective Intraarterial Cerebral Infusion of Cetuximab
6 Recruiting Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma
Conditions: Glioblastoma Multiforme;   Anaplastic Astrocytoma
Intervention: Drug: Bevacizumab and Carboplatin

Indicates status has not been verified in more than two years